To promote the innovative development of peptide drugs in China and increase industry exchanges, the Peptide Branch of the China Biopharmaceutical Industry Association willThe "2024 China Peptide Drug Innovation Conference" will be held in Chengdu on April 19-20, 2024The conference aims to create an exchange and cooperation model supported by industry, interdisciplinary integration, and innovation driven development, providing suggestions and strategies for the development of peptide innovative drugs in China.
Chutianpai Biotechnology (Changsha) Co., Ltd. (referred to as Chutianpai) is a subsidiary of Chutianpai Technology Co., Ltd. (stock code: 300358), a joint venture between Chutianpai Technology and PSI Peptide Technology Co., Ltd. in the United States, providing comprehensive peptide synthesis solutions and services for peptide research and development institutions and production enterprises.
As one of the earliest companies to provide peptide synthesis equipment, Chutian Pet has over 20 years of industry experience and profound accumulation of peptide technology. Relying on Chutian's strong manufacturing and delivery capabilities and industrial equipment technology, we form a strong alliance to meet customers' high demand for customized needs. According to different customer needs, various mixing methods can be used to achieve ideal homogeneous reactions, thereby achieving higher purity, and advanced GMP synthesis solutions can be created with technologies such as closed inlet and outlet, online drying, etc. Chutianpai has become one of the few suppliers providing peptide synthesis solutions for well-known peptide pharmaceutical companies and top research institutions.
Chutian Pat
Research and development peptide synthesizer
S890
Pilot scale large-scale peptide synthesizer
E850
GMP produced peptide synthesizer
EX870
A powerful platform for technological innovation.
As the parent company platform of Chutian Pat,Chutian TechnologyAfter more than 20 years of development, it has become one of the major enterprises in the field of pharmaceutical equipment in the world. It has established technical research institutions such as the Central Technology Research Institute located in Changsha, China, the Sichuan Provincial Pharmaceutical Design Institute located in Chengdu, China, and the European Institute of Technology located in Germany. With over 2000 technical research and development personnel, it has a deep understanding of the entire module and process of biomedicine, providing strong support for Chutianpai's technological innovation in the peptide field.
A powerful manufacturing technology platform.
While establishing a strong technological innovation platform, Chutian Technology, the parent company of Chutian Pet, has also established a powerful advanced manufacturing platform, with advanced manufacturing platforms such as ultra precision mold centers, component precision machining centers, and surface refinement treatment centers, providing strong manufacturing and delivery capabilities for Chutian Pet's peptide synthesis equipment.
A powerful industrial chain ecosystem platform.
The governments at all levels of Hunan province and city are vigorously supporting the development of the Chu Tian biopharmaceutical and life science industry chain by Chu Tian Technology, the parent company of Chu Tian Pat. The industry chain has gathered more than ten holding subsidiaries in the sub fields of biopharmaceuticals and life sciences, providing strong industry chain support for Chu Tian Pat to provide peptide synthesis whole body solutions.
Chu Tianren
Regarding the association:
China Biochemical Pharmaceutical Industry AssociationIt is the only biochemical biopharmaceutical industry association in China, a national first level association, and a non-profit organization. The leading organ of the Party's work: the Central Department of Social Work.
The association has always adhered to the principle of holding meetings for enterprises and entrepreneurs, implementing a unit membership system. Currently, it has nearly 500 member units, consisting of vice president units, executive director units, director units, and ordinary member units. Member units are mainly backbone enterprises (groups) of various economic types engaged in the production of biochemical and biological drugs, as well as related equipment and instrument enterprises. The association has established an expert committee consisting of over 600 experts from academicians, research institutes, universities, research institutions, and enterprise technical talents.
Core branch offices：
Peptide Branch (established in 2019)
Sugar Drug Branch (established in 2020)
Recombinant Drug Branch (established in 2023)
◆ Plasma Protein Branch (under preparation)
Nucleic Acid Drug Branch (under preparation)
